Insider Selling: Cerus Co. (NASDAQ:CERS) CFO Sells $46,722.00 in Stock

Cerus Co. (NASDAQ:CERS) CFO Kevin Dennis Green sold 31,148 shares of the company’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $1.50, for a total transaction of $46,722.00. Following the completion of the transaction, the chief financial officer now owns 935,754 shares in the company, valued at approximately $1,403,631. The trade was a 3.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Kevin Dennis Green also recently made the following trade(s):

• On Monday, March 3rd, Kevin Dennis Green sold 60,656 shares of Cerus stock. The stock was sold at an average price of $1.58, for a total transaction of $95,836.48.

Cerus Stock Down 0.7 %

Shares of Cerus stock opened at $1.48 on Thursday. The stock has a market cap of $274.97 million, a price-to-earnings ratio of -13.45 and a beta of 1.56. The firm’s 50-day moving average is $1.73 and its two-hundred day moving average is $1.78. Cerus Co. has a 1 year low of $1.38 and a 1 year high of $2.54. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92.

Cerus (NASDAQ:CERS) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). The business had revenue of $50.81 million during the quarter, compared to analyst estimates of $50.81 million. Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. As a group, research analysts expect that Cerus Co. will post -0.08 earnings per share for the current fiscal year.

Institutional Trading of Cerus

Several hedge funds have recently modified their holdings of CERS. Squarepoint Ops LLC raised its position in shares of Cerus by 2,084.7% in the 4th quarter. Squarepoint Ops LLC now owns 492,732 shares of the biotechnology company’s stock valued at $759,000 after purchasing an additional 470,178 shares during the last quarter. Two Sigma Advisers LP raised its position in shares of Cerus by 249.5% in the 4th quarter. Two Sigma Advisers LP now owns 254,100 shares of the biotechnology company’s stock valued at $391,000 after purchasing an additional 181,400 shares during the last quarter. Two Sigma Investments LP raised its position in Cerus by 121.6% during the 4th quarter. Two Sigma Investments LP now owns 595,234 shares of the biotechnology company’s stock worth $917,000 after buying an additional 326,605 shares during the last quarter. State of Wyoming raised its position in Cerus by 39.1% during the 4th quarter. State of Wyoming now owns 129,840 shares of the biotechnology company’s stock worth $200,000 after buying an additional 36,488 shares during the last quarter. Finally, ProShare Advisors LLC raised its position in Cerus by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 50,817 shares of the biotechnology company’s stock worth $78,000 after buying an additional 16,720 shares during the last quarter. 78.37% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $4.00 price target on shares of Cerus in a report on Friday, February 21st.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.